PDCD1 and cutaneous melanoma: Different drugs are used in immunotherapy for cutaneous melanoma, but the focus still remains on two groups, i.e., anti-PD-1 antibodies (nivolumab and pembrolizumab) and anti-CTLA-4 antibodies (ipilimumab) (Table 3).